Trial · NCT04400474
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | LungNET (Lung Typical Andatypical Carcinoids) Cabozantinib 40 mg + Atezolizumab 1200 mg | 0 | Participants | ||
| Objective Response Rate (ORR) | ATC (Anaplastic Thyroid Cancer) Cabozantinib 40 mg + Atezolizumab 1200 mg | 2 | Participants | ||
| Objective Response Rate (ORR) | ACC (Adrenocortical Carcinoma) Cabozantinib 40 mg + Atezolizumab 1200 mg | 2 | Participants | ||
| Objective Response Rate (ORR) | PPGL (Pheochromocytoma/Paraganglioma) Cabozantinib 40 mg + Atezolizumab 1200 mg | 2 | Participants | ||
| Objective Response Rate (ORR) | G1-2 GEP-NET (Well-differentiated Gastroenteropancreatic NET) | 4 | Participants | ||
| Objective Response Rate (ORR) | G3 EP-NEN (Extrapulmonary Neuroendocrine Neoplasms.) | 0 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) | LungNET (Lung Typical and Atypical Carcinoids) | 8 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) | ATC (Anaplastic Thyroid Cancer) | 11 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) | ACC (Adrenocortical Carcinoma) | 18 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) | PPGL (Pheochromocytoma/Paraganglioma) | 11 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) | G1-2 GEP-NET (Well-differentiated Gastroenteropancreatic NET) | 22 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) | G3 EP-NEN (Extrapulmonary Neuroendocrine Neoplasms.) | 8 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) Related With Atezolizumab | LungNET (Lung Typical and Atypical Carcinoids) | 7 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) Related With Atezolizumab | ATC (Anaplastic Thyroid Cancer) | 7 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) Related With Atezolizumab | ACC (Adrenocortical Carcinoma) | 15 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) Related With Atezolizumab | PPGL (Pheochromocytoma/Paraganglioma) | 10 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) Related With Atezolizumab | G1-2 GEP-NET (Well-differentiated Gastroenteropancreatic NET) | 21 | Participants | ||
| Safety Profile Number of Adverse Events Reactions (TRAEs) Related With Atezolizumab | G3 EP-NEN (Extrapulmonary Neuroendocrine Neoplasms.) | 6 | Participants | ||
| Duration of Response (DoR) | ATC (Anaplastic Thyroid Cancer) | 20.4 | Full Range 11.5 to 20.9 | months | |
| Duration of Response (DoR) | ACC (Adrenocortical Carcinoma) | 13.1 | Full Range 5.4 to 20.9 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04400474/results